Last updated July 18, 2026
Key finding
HSI decreased from 50.7 ± 5.9 to 47.7 ± 6.5 in the NB group (p < 0.001).
This study examined the effects of Naltrexone/Bupropion on hepatic health in patients with Type 2 diabetes and obesity, finding significant improvements in hepatic steatosis and fibrosis markers.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study examined the effects of Naltrexone/Bupropion on hepatic health in patients with Type 2 diabetes and obesity, finding significant improvements in hepatic steatosis and fibrosis markers.
Improving liver health is crucial for patients with Type 2 diabetes and obesity, as it can reduce the risk of serious complications like liver disease. This study suggests that Naltrexone/Bupropion may be an effective treatment option to achieve weight loss and enhance liver function, which could lead to better overall health outcomes.
Limited sample size may affect generalizability. Short duration of the study may not capture long-term effects. Lack of diverse population limits applicability.
Published in
Publication details and source links for this paper.
Alina NS, Laura AMK, Carmen AWD, et al. Weight Loss as a Key Driver of Hepatic Improvements in Patients with Type 2 Diabetes and Obesity. Diabetes, Obesity & Metabolism. 2025;27(11):6624-6631. doi:10.1111/dom.70071
HSI decreased from 50.7 to 47.7 in the NB group (p < 0.001).
MAF-5 decreased from 3.1 to 2.3 in the NB group (p < 0.001).
HSI decreased from 49.9 to 48.7 in the placebo group (p < 0.001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Naltrexone/Bupropion (NB) and Change in Hepatic Steatosis Index (HSI), Change in Metabolic Dysfunction-Associated Fibrosis-5 (MAF-5), FIB-4 index.
This study contributes evidence to
Primary intervention
Naltrexone/Bupropion (NB)
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
3
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Naltrexone/Bupropion (NB) → Change in Hepatic Steatosis Index (HSI)
Naltrexone/Bupropion (NB) → Change in Hepatic Steatosis Index (HSI)
Naltrexone/Bupropion (NB) → Change in Metabolic Dysfunction-Associated Fibrosis-5 (MAF-5)
Naltrexone/Bupropion (NB) → Change in Metabolic Dysfunction-Associated Fibrosis-5 (MAF-5)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Naltrexone/Bupropion (NB) and FIB-4 index, Naltrexone/Bupropion (NB) and Change in Hepatic Steatosis Index (HSI).
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Change in Hepatic Steatosis Index (HSI)
Measures Change in Hepatic Steatosis Index (HSI) as a key outcome.
All studies measuring FIB-4 index
Measures FIB-4 index as a key outcome.
All studies on Naltrexone/Bupropion (NB)
Contributes to Naltrexone/Bupropion (NB) evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Naltrexone/Bupropion (NB) appears to improve Change in Hepatic Steatosis Index (HSI).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in Hepatic Steatosis Index (HSI)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Naltrexone/Bupropion (NB) for FIB-4 index.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
FIB-4 index
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Naltrexone/Bupropion (NB) may worsen Change in Metabolic Dysfunction-Associated Fibrosis-5 (MAF-5) or be associated with harm.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in Metabolic Dysfunction-Associated Fibrosis-5 (MAF-5)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | moderate negative | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
